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JOINS, an herbal anti-arthritic drug, was developed for the treatment and pain relief of knee osteo-
arthritis. It was approved for use in Korea by the Ministry of Food and Drug Safety in 2001. The aim 
of this study was to investigate the effect of JOINS on the pharmacokinetic (PK) profiles of aceclof-
enac in healthy adults. A PK drug-drug interaction study was conducted in 61 healthy subjects by 
using an open-label, multiple-dose, one sequence, two-period design. Blood samples were collected 
for plasma concentrations of aceclofenac during the reference period (aceclofenac 100 mg alone) 
and interaction period (aceclofenac 100 mg + JOINS 300 mg). The area under the curve within 
a dosing interval (τ) at steady state (AUCτ,ss) and the Cmax at steady state (Cmax,ss) of aceclofenac 
were analyzed by a non-compartment model using the Phoenix® WinNonlin® software version 6.3 
(Pharsight, Mountain View, CA, USA). The 90% CIs of the geometric mean ratios (GMRs) of the 
AUCτ,ss of aceclofenac with JOINS to without JOINS (D4/D3 and D11/D3) were 0.9593–1.0130 and 
0.9745–1.0291, respectively, and the corresponding values for the Cmax,ss of aceclofenac with JOINS 
to without JOINS (D4/D3 and D11/D3) were 0.8578–0.9795 and 0.8510–0.9717. Aceclofenac alone 
or co-administered with JOINS was safe and well tolerated with no serious adverse drug reactions 
or significant differences in the severity of adverse events (AEs) between the two treatment groups. 
We conclude that co-administration of aceclofenac with JOINS does not influence the PK and safety 
profiles of aceclofenac.
Introduction
  Osteoarthritis (OA) is the most common chronic joint disease 
causing pain, ankylosis, edema, and joint degeneration. With 
the increase in the elderly population and obesity, the incidence 
of osteoarthritis is gradually increasing.[1] According to the 
5th Korea National Health and Nutrition Examination Survey 
(KNHANES) in 2010, 14.7% of adults aged over 50 years and 
29.6% of the elderly aged over 70 years were suffering from os-
teoarthritis.
  According to the recommendation of Osteoarthritis Research 
Society International (OARSI) for the management of hip and 
knee osteoarthritis,[2] acetaminophen is recommended as the 
first-line treatment for pain relief;[3] however, it shows low ef-
ficacy in some patients. Nonsteroidal anti-inflammatory drugs 
(NSAIDs) are commonly used because they are reported to be 
more effective for achieving pain relief than is acetaminophen. 
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However, the Drug Utilization Review (DUR) in Korea forbids 
administration of more than two concomitant NSAIDs because 
of the occurrence of side effects such as hemorrhages, heart-
burn, nausea, and upper gastrointestinal ulcer bleeding.
  Aceclofenac is an NSAID that blocks the production of pros-
taglandins by inhibiting cyclooxygenase (COX).[4,5] It is the 
most frequently prescribed drug for the treatment of OA in 
Korea. In a randomized, double-blind trial, the clinical efficacy 
of aceclofenac for knee OA was similar to that of diclofenac and 
piroxicam.[6] Furthermore, the risk of gastrointestinal side ef-
fects was lower in the aceclofenac group than in the diclofenac 
group in preclinical trials[6] and in a multicenter, randomized, 
double-blind study of OA patients.[7]
  JOINS is an herbal anti-arthritic agent extracted from Clematis 
mandshurica, Trichosanthes kirilowii, and Prunella vulgaris. It 
was developed by SK Chemical Co. Ltd. and its use was ap-
proved by the Korean Ministry of Food and Drug Safety in 
2001. JOINS is indicated for the relief of pain in OA and rheu-
matoid arthritis. In a randomized, double-blind trial of JOINS 
in patients with knee OA, the efficacy of JOINS for pain relief 
was proven non-inferior compared to that of diclofenac. It was 
also demonstrated that the incidence of drug-related adverse 
events (AEs) was significantly lower than that observed for di-
clofenac.[8] In a cartilage explant culture study, JOINS inhibited 
proteoglycan (PG) degradation and significantly protected the 
knee joint of rabbits to an extent similar to that shown in the 
collagenase-induced OA model (control group).[9] Further-
more, in animal studies, JOINS significantly protected against 
the damage due to diclofenac-induced gastric ulcerations.[10] 
  Unlike NSAIDs, JOINS has different mechanisms of action 
for protecting the knee joint that relieve symptoms of OA and 
show gastrointestinal AEs, which are common in patients us-
ing NSAIDs. Thus, co-administration of JOINS with NSAIDs 
is expected to be a more effective OA treatment. According to 
the UBIST data (2012), in 77.6% of the cases of JOINS co-pre-
scribed with NSAIDs, no remarkable side effects were observed. 
Thus, the anti-arthritic efficacy and protection against NSAID-
induced side effects of JOINS co-administered with NSAIDs 
have already been demonstrated by the actual prescribing 
practice according to the data of the Korean Health Insurance 
Review and Assessment service. A fixed-dose combination of 
JOINS 300 mg and aceclofenac 100 mg may benefit the medi-
cal practice as it may improve compliance. However, before 
conducting clinical trials to assess the 
efficacy of this fixed-dose combination 
treatment, a study of the potential drug-
drug interactions between both drugs 
is needed. Therefore, the objective of 
this study was to investigate the effect 
of JOINS on the pharmacokinetic (PK) 
profiles of aceclofenac in healthy male 
adults. 
Method
  This study was conducted at the Clinical Trials Center (CTC) 
of Yonsei University Severance Hospital (Seoul, Korea), and the 
protocol was approved by the Institutional Review Board (IRB) 
at Severance Hospital. It was conducted in accordance with the 
principles of the Declaration of Helsinki and Good Clinical 
Practice standards. Written informed consents were obtained 
from all subjects before study enrollment.
  The investigational drugs were JOINS 300 mg (SK Chemical 
Co. Ltd., Seongnam, Korea) and aceclofenac 100 mg (Daewoong 
Pharmaceuticals Co. Ltd., Seoul, Korea). To assess potential PK 
drug interactions, it was recommended that the subjects receive 
the following approved maximum dose of both drugs: 200 mg 
per day (100 mg twice daily) of aceclofenac and 600 mg per day 
(200 mg thrice daily) of JOINS. In anticipation of developing a 
fixed-dose combination of aceclofenac and JOINS in a future 
study, the study was designed such that the subjects received 
JOINS 300 mg twice daily instead of the approved regimen of 
JOINS 200 mg thrice daily. 
Study Population
  Healthy male volunteers aged 20 to 50 years with a body 
mass index between 18.5 and 25 kg/m2 were recruited for this 
study, and were screened according to the following inclusion 
criteria: volunteers in clinically good health conditions accord-
ing to standard laboratory tests (hematology, blood chemistry, 
immune-serum levels, and urinary) and 12-lead electrocardio-
gram (ECG). Volunteers who experienced hypersensitivity reac-
tions or allergy to the study drugs (NSAID class drugs including 
aceclofenac, JOINS, or their additives), or had any other disease 
or medical history of abnormality were excluded from the study. 
Study Design
  This study was an open-label, multiple-dose, one-sequence, 
two-period study. All subjects received aceclofenac 100 mg 
alone twice daily for 3 days (Days 1 to 3), followed by aceclof-
enac 100 mg and JOINS 300 mg in combination twice daily for 
8 days (Days 4 to 11) (Fig. 1)
  All subjects visited the Clinical Trials Center of the Severance 
Hospital twice (8 a.m. and 8 p.m.) on Day 1 and on 8 a.m. on 
Day 2, and received aceclofenac 100 mg with 240 mL water. The 
subjects started taking each meal at least 30 min before admin-
istration of the study drugs and finished eating within 20 min. 
Figure 1. Study design.
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The subjects were hospitalized by 6 p.m. on Day 2 and were 
required to abstain from strenuous exercise, having a snack, 
smoking, and consuming alcohol- and xanthine-containing 
drinks during the entire study days. All eligible subjects received 
aceclofenac 100 mg twice daily (8 a.m. and 8 p.m.) on Day 2 and 
Day 3. 
  Subjects received aceclofenac 100 mg plus JOINS 300 mg with 
240 mL water at 8 a.m. and 8 p.m. on Day 4 under fasting con-
ditions. Afterward, the subjects were discharged; they revisited 
the hospital on Day 5 to 10 to receive aceclofenac 100 mg with 
JOINS 300 mg twice daily (8 a.m. and 8 p.m.). By 6 p.m. on Day 
10, the subjects were re-hospitalized and followed the same pre-
determined time schedule as that during the first hospitaliza-
tion. 
  The subjects who completed all study schedules returned for a 
follow-up visit within 7 days (±2 days).
Sample Size Calculation
  The intra-subject coefficients of variation (CVw) for the maxi-
mum plasma concentration (Cmax) and area under the plasma 
concentration-time curve up to the last measurable concentra-
tion (AUClast) of aceclofenac 100 mg were assumed to be 24.85% 
and 10.26%, respectively, based on the results of a previous 
study.[11] Using the greatest CVw, 24.85% and its point estimate, 
1.085, at a 0.05 significance level with 90% power, the required 
sample size was calculated to be 54 subjects. The total sample 
size was estimated to be 64 subjects, assuming a drop-out rate of 
15%. 
Sample Collection and Bioanalytical Methods
The time to Cmax (tmax) and half-life (t1/2) of aceclofenac were 
0.66–1.7 h and 1.4–5.4 h, respectively, according to the results 
of previous PK studies.[11-13] Blood samples were collected at 
0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, and 12 h after ad-
ministration (12 times per day) on the basis of the tmax, t1/2 and 
administration interval (12 h). Blood samples were collected on 
Day 3 when the steady state of aceclofenac was achieved, and on 
Day 4 and Day 11 when aceclofenac and JOINS were co-admin-
istered. Additionally, blood samples were collected at 8 a.m. on 
Day 5, 7 and 9 before drug administration to assess the Ctrough 
of each day. A total of 39 samples were collected per subject. A 
washout period was not included in this study.
  Plasma samples for the determination of the aceclofenac con-
centrations were analyzed by Biocore Co. Ltd., Seoul, South 
Korea. A validated LC-MS/MS plasma assay with a lower limit 
of quantification of 0.3 μg/mL for aceclofenac was used. This 
method had adequate linearity (r > 0.9950) within the concen-
tration ranges of 0.3 to 100 μg/mL. The inter-assay variability 
was determined with a coefficient of variation of 3 different 
control samples containing nominal concentrations of 0.9, 5.0, 
and 80 μg/mL aceclofenac.
Pharmacokinetics Analysis
  PK analysis was performed using the Per Protocol Set in which 
the subjects completed all study schedules. The primary end-
points were the AUC within a dosing interval (τ) at steady state 
(AUCτ,ss) and the Cmax at steady state (Cmax,ss) of aceclofenac. The 
secondary endpoints were the AUC extrapolated to infinity at 
steady state (AUCinf, ss), the time to reach Cmax,ss (tmax,ss), t1/2, the 
minimum plasma concentration at steady state (Cmin,ss), the av-
erage plasma concentration at steady state (Cavg,ss), and fluctua-
tion [(Cmax,ss−Cmin,ss)/Cavg,ss] of aceclofenac. 
Safety Analysis
  Safety analysis was performed for the safety set of subjects who 
received at least one dose of the study drug. All AEs were re-
ported. The safety profile evaluations were based on vital signs, 
physical examinations, 12-lead ECGs, and clinical laboratory 
tests.
Statistical Analysis
  The PK parameters were evaluated by a non-compartment 
method using the Phoenix® WinNonlin® software version 
6.3 (Pharsight, Mountain View, CA, USA). The AUCτ,ss and 
Cmax,ss were transformed to a natural log scale. Using the log-
transformed data, a mixed effect model with subjects (nested in 
sequence) as a random effect was developed to compare the PK 
values between the treatment conditions. The GMRs of aceclof-
enac combined with JOINS to aceclofenac alone were calculated 
to determine whether its 90% CIs were entirely contained with-
in the range of 0.8–1.25. Safety profile analyses were evaluated 
using descriptive statistics. At the discretion of the investigator, 
inferential tests (such as repeated ANOVA and McNemar’s test) 
were performed on measurements considered clinically signifi-
cant, if necessary. 
Results
Study Subjects
  A total of 90 healthy volunteers were enrolled for screening 
and 64 volunteers participated in the study on the basis of the 
inclusion and exclusion criteria. Sixty-one subjects (95.3%) 
completed the study schedule and 3 subjects (4.7%) dropped 
out because of consent withdrawal (2 subjects) and loss to fol-
low-up (1 subject). All subjects were male. The mean (standard 
deviation, SD) age, weight, height, and BMI are shown in Table 1.
Pharmacokinetics          
  The mean plasma concentration-time profiles of aceclofenac 
with or without JOINS are shown in Figure 2. The PK param-
eters are summarized in Table 2. The AUCτ,ss and Cmax,ss of 
aceclofenac administered alone were not significantly differ-
ent from that of aceclofenac co-administered with JOINS. The 
other PK values, i.e., Cmin,ss and Cavg,ss, were also similar between 
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the two treatment conditions. The tmax at Day 4 was slightly dif-
ferent from that at Day 3 or 11. However, the non-parametric 
test revealed no significant difference in the tmax of aceclofenac 
between the two treatment conditions.
  The GMRs of aceclofenac co-administered with JOINS to ace-
clofenac alone are shown in Table 2. The GMRs of the AUCτ,ss of 
aceclofenac with to without JOINS (D4/D3 and D11/D3) were 
0.9858 and 1.0015, respectively. The GMRs of Cmax,ss of aceclof-
enac with JOINS to without JOINS (D4/D3 and D11/D3) were 
0.9166 and 0.9093, respectively. The predose plasma concentra-
tions (μg/mL) of aceclofenac on Day 5, Day 7, and Day 9 were 
0.096, 0.211 and 0.124, respectively. 
Safety and Tolerability
  During the study days, 31 AEs were reported in 26 subjects: 6 
subjects (7 cases) who received aceclofenac alone and 22 sub-
jects (24 cases) who received aceclofenac combined with JOINS. 
AEs were significantly less frequent in the aceclofenac alone 
group than in the aceclofenac-JOINS co-administration group 
(p = 0.001, McNemar’s test). One subject suffered from a serious 
AE (SAE) caused by a traffic accident (TA), which was not re-
lated to the study drug. Drug-related AEs (dyspepsia, aphthous 
stomatitis, and abdominal discomfort) occurred in 4 subjects (4 
cases) who received aceclofenac alone and in 9 subjects (9 cases) 
who received aceclofenac combined with JOINS. There was no 
statistically significant difference in drug-related AE profiles 
between aceclofenac administered alone and aceclofenac co-
administered with JOINS (p = 0.132, McNemar’s test), and no 
occurrence of any significant changes in vital signs, physical 
examination results, 12-lead ECGs, and clinical lab tests. 
Discussion
  To develop a fixed-dose combination of aceclofenac and 
JOINS, a drug-drug interaction study is needed. Therefore, here, 
we explored potential PK interactions between aceclofenac 100 
mg and JOINS 300 mg affecting the PK properties in healthy 
male volunteers. Because JOINS is a special natural herbal prod-
uct consisting of various natural ingredients, the mechanism of 
action underlying its specific effects is unknown. Further, the 
specific drug ingredients and their metabolites have not been 
explored before. These reasons preclude assessment of the PK 
profiles of JOINS. However, to assess the PK effects of JOINS on 
aceclofenac, the present study was designed as an open-label, 
multiple-dose, one-sequence, two-period study.
  The full PK blood sampling was performed on Day 3, 4 and 11. 
To evaluate the PK properties of aceclofenac administered alone 
at steady state, blood samples were collected 48 hours after the 
first dosing (Day 3), which was five times the maximum t1/2 of 
aceclofenac (5.4 h). Since the t1/2 of aceclofenac 100 mg in the 
present study (1.9–2.1 h) was lower than that reported by other 
studies,[11-13] it was postulated that the steady state concentra-
tion would be achieved by Day 3. To our knowledge, thus far, 
the PK of JOINS has not been reported. To assign enough time 
Table 1. Characteristics of the study participants*
Characteristics Total(N = 64)
Age (years)
Mean (SD) 
Min 
Max 
27.8 (5.0)
20.0
45.0
Weight (kg)
Mean (SD) 
Min 
Max
70.2 (7.3)
55.5
90.2
Height (cm)
Mean (SD) 
Min 
Max
176.1 (6.0)
161.9
191.5
BMI (kg/m2)
Mean (SD) 
Min 
Max
22.6 (1.6)
19.2
24.9
*All subjects were male.
Figure 2. Mean (SD) plasma concentration-time profiles of aceclof-
enac with or without JOINS (upper graph: linear, lower graph: log-
linear).Treatment: aceclofenac 100 mg alone (Day 3), aceclofenac 100 
mg with JOINS 300 mg (Day 4 and Day 11), τ = 12 h.
A
B
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to investigate the induction of drug metabolism, a 7-day period 
of co-administering aceclofenac with JOINS was chosen, and 
blood samples were collected 7 days after the first dosing (Day 
11). Since aceclofenac and JOINS are to be used as a long-term 
therapy in OA patients, evaluating the PK profiles of both drugs 
at steady state with multiple dosing schedules is appropriate.
  The aceclofenac PK parameters found in this study were com-
parable to those obtained in previous studies.[11,12] The pres-
ent study also showed that the AUCτ,ss and Cmax,ss of aceclofenac 
at steady state were comparable to those of aceclofenac co-
administered with JOINS. The 90% CI GMRs of the AUCτ,ss and 
Cmax,ss of aceclofenac were within the range of 0.8–1.25. These 
results indicated that the PK of aceclofenac was not changed by 
JOINS.
  The multiple dosing schedule of aceclofenac with or with-
out JOINS was well tolerated in this study population. The 
frequency of AEs was significantly higher in the aceclofenac-
JOINS co-administration group than that in the aceclofenac 
alone group. However, all AEs were mild in severity (except in 1 
case), and there were no significant differences in the severity of 
AEs between the two groups. Further, there was no statistically 
significant difference in adverse drug reactions between the two 
groups. 
  Overall, the present study indicates that the co-administration 
of JOINS with aceclofenac does not affect the systemic exposure 
to aceclofenac. Moreover, JOINS does not inhibit the metabo-
lism of aceclofenac by cytochrome P450 2C9. Therefore, we 
conclude that the co-administration of aceclofenac with JOINS 
does not influence the PK and safety profiles of aceclofenac. 
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